Concise Synthesis of Molnupiravir

Concise Synthesis of Molnupiravir

Author: ChemistryViews

Molnupiravir (pictured) is an oral antiviral drug for the treatment of COVID-19. It is a nucleoside analog originally developed to treat influenza. Molnupiravir works against viral infections by interfering with viral RNA replication.

John A. McIntosh, Patrick S. Fier, Merck & Co., Inc., Rahway, NJ, USA, and colleagues have developed a short, high-yielding, and sustainable three-step synthesis of molnupiravir. The team started from ribose and used a biocatalytic cascade to synthesize the target compound.

Ribose was first 5-acylated using isobutyric anhydride and an immobilized lipase enzyme. Then, the resulting 5-isobutyryl ribose was converted to ribosyl-1-phosphate and reacted with uracil using several optimized enzymes, including an engineered ribosyl-1-kinase and uridine phosphorylase. In a final step, an oxime group was introduced at the uracil unit, using hexamethyldisilazane (HMDS), NH4HSO4, and imidazole to promote the transformation.

The new synthetic route is much shorter and has a seven-fold higher overall yield than the originally used route. Since it uses only simple raw materials and enzymes, it could provide a rapid supply of molnupiravir on a large scale.



Also of Interest

  • Collection: SARS-CoV-2 Virus
    What we know about the new coronavirus and COVID-19

 

News: Coronavirus Drug Molnupiravir

  • 05 October 2021

Molnupiravir significantly reduces risk of hospitalization and/or death, according to Merck

thumbnail image: Coronavirus Drug Molnupiravir

News: Improved Synthesis Route for Molnupiravir

  • 04 August 2021

Efficient synthesis from cheap and easily available cytidine

thumbnail image: Improved Synthesis Route for Molnupiravir

Research Highlight: How Molnupiravir Causes SARS-CoV-2 to Mutate and Die

  • 07 September 2021

Mechanism might apply to various viral polymerases and could explain broad-spectrum antiviral activity of molnupiravir

thumbnail image: How Molnupiravir Causes SARS-CoV-2 to Mutate and Die

News: High-Yielding Synthesis of Antiviral Drug Candidate

  • 19 November 2020

Improved preparation of EIDD‐2801, currently in clinical trials for COVID-19 treatment

thumbnail image: High-Yielding Synthesis of Antiviral Drug Candidate

News: Oral Drug Blocks SARS-CoV-2 Transmission in Ferrets

  • 09 December 2020

Repurposed ribonucleoside analogue inhibitor of influenza viruses

thumbnail image: Oral Drug Blocks SARS-CoV-2 Transmission in Ferrets

 

 

Leave a Reply

Your email address will not be published.